← Biodexa Pharmaceuticals Plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income | — | — | — | — | — | — | ($7.7m) |
($7.1m)
+7.54%
|
($5.7m)
+19.07%
|
($6.4m)
-11.43%
|
($6.4m)
0.00%
|
|
| Profit or Loss | ($20.2m) | ($16.1m) | ($15.0m) | ($10.1m) | ($22.2m) | ($5.5m) | ($7.7m) | ($7.1m) | ($5.7m) | ($6.4m) | — | |
| Amortization Cash Flow | — | — | — | — | — | — | $3k | $3k | $2k | $1k | — | |
| Amortization Of Intangibles | — | — | — | — | — | — | $3k | $3k | $2k | $1k | $1k | |
| Depreciation | — | — | — | — | — | — | $340k | $280k | $252k | $188k | $188k | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $343k | $283k | $254k | $189k | $189k | |
| Adjustments For Deferred Tax Of Prior Periods | ($435k) | — | — | — | — | — | — | — | — | — | — | |
| Deferred Tax | — | — | — | — | — | — | ($832k) | ($406k) | ($250k) | ($105k) | ($105k) | |
| Adjustments For Share-Based Payments | $203k | $520k | ($36k) | ($34k) | ($404k) | $89k | $123k | $28k | $283k | $170k | — | |
| Asset Impairment Charge | — | — | — | — | — | — | $207k | $79k | $0 | $373k | $373k | |
| Change In Working Capital | — | — | — | — | — | — | $520k | ($49k) | ($3.7m) | $1.7m | $1.7m | |
| Change In Receivables | — | — | — | — | — | — | $7k | $365k | ($6.0m) | $2.6m | $2.6m | |
| Capital Expenditure | — | — | — | — | — | — | ($62k) | ($263k) | ($774k) | ($691k) | ($691k) | |
| Adjustments For Gain Loss On Disposal Of Investments In Subsidiaries Joint Ventures And Associates | — | — | ($9.3m) | $947k | — | — | — | — | — | — | — | |
| Net Other Investing Changes | — | — | — | — | — | — | ($207k) | ($79k) | — | — | ($79k) | |
| Proceeds From Borrowings Classified As Financing Activities | $65k | $5.2m | — | — | — | — | — | — | — | — | — | |
| Repayments Of Borrowings Classified As Financing Activities | $235k | $552k | $5.8m | $577k | — | — | — | — | — | — | — | |
| Issuance Of Debt | — | — | — | — | — | $0 | $0 | $0 | $431k | — | $0 | |
| Long Term Debt Issuance | — | — | — | — | — | $0 | $0 | — | — | — | $0 | |
| Long Term Debt Payments | — | — | — | — | — | — | ($178k) | ($188k) | ($186k) | ($246k) | ($246k) | |
| Net Issuance Payments Of Debt | — | — | — | — | — | — | ($178k) | ($188k) | $245k | ($696k) | ($696k) | |
| Net Long Term Debt Issuance | — | — | — | — | — | — | ($178k) | ($188k) | $245k | ($696k) | ($696k) | |
| Net Short Term Debt Issuance | — | — | — | — | — | — | $0 | $0 | $431k | — | $431k | |
| Repayment Of Debt | — | — | — | — | — | — | ($178k) | ($188k) | ($186k) | ($246k) | ($246k) | |
| Common Stock Issuance | — | — | — | — | — | — | $243k | $10.4m | $8.3m | $13.7m | $13.7m | |
| Issuance Of Capital Stock | — | — | — | — | — | — | $243k | $10.4m | $8.3m | $13.7m | $13.7m | |
| Cash Dividends Paid | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Beginning Cash Position | — | — | — | — | — | — | $10.1m | $2.8m | $6.0m | $1.7m | $1.7m | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Additional Financial Items | ||||||||||||
| Adjustments For Decrease Increase In Trade Account Receivable | ($242k) | ($968k) | $1.0m | $725k | $493k | ($487k) | $7k | $365k | ($6.0m) | $2.6m | — | |
| Adjustments For Income Tax Expense | ($9.2m) | ($1.3m) | ($2.0m) | ($1.8m) | ($1.3m) | ($646k) | ($832k) | ($406k) | ($250k) | ($105k) | — | |
| Adjustments For Increase Decrease In Trade Account Payable | $358k | ($267k) | ($3.0m) | $1.1m | ($2.0m) | ($130k) | $356k | ($207k) | $2.2m | ($913k) | — | |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $31k | ($39k) | $212k | $131k | $96k | $12k | $9k | $164k | ($93k) | $343k | — | |
| Goodwill | — | $13.4m | $22.9m | $23.0m | $0 | — | — | — | — | — | $373k | |
| Income Taxes Paid Refund Classified As Operating Activities | ($1.6m) | ($1.5m) | ($1.4m) | ($1.9m) | ($2.0m) | ($1.2m) | ($678k) | ($845k) | ($129k) | ($707k) | — | |
| Interest Paid Classified As Financing Activities | $74k | $111k | $587k | $30k | $34k | $15k | $18k | $13k | $0 | $14k | — | |
| Payments Of Lease Liabilities Classified As Financing Activities | — | — | — | $450k | $258k | ($112k) | $178k | — | — | — | — | |
| Proceeds From Issuing Shares | $15.6m | $5.7m | — | $14.1m | $9.7m | $9.0m | $243k | $10.4m | $8.3m | $13.7m | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | $19k | $778k | — | $9k | — | — | — | — | — | — | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | $47k | $10.2m | $8.6m | $13.0m | $13.0m | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | ($220k) | ($265k) | ($598k) | ($583k) | ($583k) | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | ($7.2m) | $3.1m | ($4.3m) | $6.9m | — | |
| Change In Other Working Capital | — | — | — | — | — | — | $157k | ($207k) | — | — | ($207k) | |
| Change In Payable | — | — | — | — | — | — | $356k | ($207k) | $2.2m | ($913k) | ($913k) | |
| Changes In Cash | — | — | — | — | — | — | ($7.2m) | $3.1m | ($4.3m) | $6.9m | $6.9m | |
| End Cash Position | — | — | — | — | — | — | $2.8m | $6.0m | $1.7m | $8.5m | $8.5m | |
| Financing Cash Flow | — | — | — | — | — | — | $47k |
$10.2m
+21657.45%
|
$8.6m
-16.32%
|
$13.0m
+52.38%
|
$13.0m
0.00%
|
|
| Free Cash Flow | — | — | — | — | — | — | ($7.1m) | ($7.1m) | ($13.0m) | ($6.3m) | ($6.3m) | |
| Gain Loss On Investment Securities | — | — | — | — | — | — | ($468k) | ($487k) | ($3.2m) | ($2.3m) | ($2.3m) | |
| Gain Loss On Sale Of PPE | — | — | — | — | — | — | $14k | $2k | $4k | $29k | $29k | |
| Interest Received CFI | — | — | — | — | — | — | $29k | $73k | $176k | $90k | $90k | |
| Investing Cash Flow | — | — | — | — | — | — | ($220k) | ($265k) | ($598k) | ($583k) | ($583k) | |
| Net Foreign Currency Exchange Gain Loss | — | — | — | — | — | — | ($1k) | $0 | $4k | ($130k) | ($130k) | |
| Net Intangibles Purchase And Sale | — | — | — | — | — | — | $0 | ($237k) | ($765k) | ($689k) | ($689k) | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | ($42k) | ($22k) | ($9k) | $16k | $16k | |
| Operating Gains Losses | — | — | — | — | — | — | ($455k) | ($485k) | ($3.2m) | ($2.4m) | ($2.4m) | |
| Other Non Cash Items | — | — | — | — | — | — | $24k | ($42k) | ($2k) | $140k | — | |
| Purchase Of Intangibles | — | — | — | — | — | — | $0 | ($237k) | ($765k) | ($689k) | ($689k) | |
| Purchase Of PPE | — | $707k | $244k | $310k | $209k | $320k | ($62k) | ($26k) | ($9k) | ($2k) | ($691k) | |
| Sale Of PPE | — | — | — | — | — | — | $20k | $4k | $0 | $18k | $18k | |
| Stock Based Compensation | — | — | — | — | — | — | $123k | $28k | $283k | $170k | $170k |